U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H29NO5S
Molecular Weight 395.513
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LATRUNCULIN B

SMILES

C[C@H]1CC[C@@H]2C[C@H](C[C@@](O)(O2)[C@@H]3CSC(=O)N3)OC(=O)C=C(C)CCC=C1

InChI

InChIKey=NSHPHXHGRHSMIK-JRIKCGFMSA-N
InChI=1S/C20H29NO5S/c1-13-5-3-4-6-14(2)9-18(22)25-16-10-15(8-7-13)26-20(24,11-16)17-12-27-19(23)21-17/h3,5,9,13,15-17,24H,4,6-8,10-12H2,1-2H3,(H,21,23)/b5-3-,14-9-/t13-,15-,16-,17+,20-/m1/s1

HIDE SMILES / InChI

Molecular Formula C20H29NO5S
Molecular Weight 395.513
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Latrunculin B originates from Latrunculia (now Negombata) magnifica, a sponge from the Red Sea. Latrunculin B inhibits the assembly of actin microfilaments by 1:1 molecular binding of free actin monomers in the cell cytoplasm. It may be a potential therapeutic agent for glaucoma. Latrunculin B induced destabilization of the actin microfilament and apoptosis in a dose-dependent manner, as demonstrated by morphological changes and nuclear condensation in the PC3M cells. In addition, it resulted in an increase in the levels of gamma-H2AX recruitment, implicating the induction of DNA damage, including double-strand breaks. Induction of Bax, with little effect on Bcl-2 expression, indicated that actin disruption causes apoptosis through activation of Bax signaling in PC3M cells. This data might helps to develop the strategy for actin-based anticancer chemotherapy against highly metastatic prostate cancer.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
60.0 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​

PubMed

Sample Use Guides

In Vivo Use Guide
Lat-B ophthalmic solutions, 0.005%, 0.01%, 0.02%, or 0.05% in one eye over 3 days (5 single-dose instillations, separated by 12 hours).
Route of Administration: Topical
In Vitro Use Guide
PC-3 cells were treated with 0.5 uM of Latrunculin B under serum-starved conditions (0.5% FBS) for 24 h and gene expression assessed with an Affymetrix gene chip. Latrunculin B produced significant effects on expression of genes involved in purine and pyrimidine metabolism.
Substance Class Chemical
Record UNII
LW7U308U7U
Record Status Validated (UNII)
Record Version